Methylenetetrahydrofolate reductase deficiency is the most common inborn error of folate metabolism and should be suspected when homocystinuria is combined with hypomethioninemia. The main clinical findings are neurologic signs such as severe developmental delay, marked hypotonia, seizures, microcephaly, apnea, and coma. Most patients present in early life. The infantile form is severe, with rapid deterioration leading to death usually within 1 year. Treatment with betaine has been shown to be efficient in lowering homocysteine concentrations and returning methionine to normal, but the clinical response is variable. We report two brothers with methylenetetrahydrofolate reductase deficiency: the first was undiagnosed and died at 8 months of age from neurologic deterioration and apnea, while his brother, who was treated with betaine from the age of 4 months, is now 3 years old and has developmental delay. (J Child Neurol 2000;15:539—543).
Get full access to this article
View all access options for this article.
References
1.
Ogier de Baulny H., Gerard M., Saudubray JM, Zittoun J.: Remethylation defects: Guidelines for clinical diagnosis and treatment. Eur J Pediatr1998 ;157(Suppl 2):S77-S83.
2.
Zittoun J.: Congenital errors of folate metabolism. Baillieres Clin Haematol1995;8:603-616.
3.
Finkelstein JD: The metabolism of homocysteine pathways and regulation. Eur J Pediatr1998;157(Suppl 2):540-544.
4.
Rosenblatt DS : Inherited disorders of folate transport and metabolism, in Scriver CR, Beaudet AL, Sly WS, et al (eds): The Metabolic and Molecular Bases of Inherited Disease , 7th ed. New York, McGraw-Hill, 1995, pp 3111-3128.
5.
Matthews RG, Sheppard C., Goulding C.: Methylenetetrahydrofolate reductase and methionine synthase: Biochemistry and molecular biology. Eur J Pediatr1998;157(Suppl 2):554-559.
6.
Grieco AJ: Homocystinuria pathogenetic mechanisms. Am JMed Sci1977;273:120-132.
7.
Kishi T., Kawamura I., Harada Y., et al: Effect of betaine on S-adenosylmethionine levels in the cerebrospinal fluid in a patient with methylenetetrahydrofolate reductase deficiency and peripheral neuropathy. J Inherit Metab Dis1994;17:560-565.
8.
Welch GN, Loscalzo J.: Homocysteine and atherothrombosis. N Engl J Med1998;338:1042-1050.
9.
Berlow S., Bacman RP, Berry GT, et al: Betaine therapy in homocystinemia. Brain Dysfunct1989;2:10-24.
10.
Goyette P., Frosst P., Rosenblatt DS, Rozen R.: Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet1995;56:1052-1059.
11.
Holme E., Kjellman B., Ronge E.: Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Child1989;64:1061-1064.
12.
Von Dobelin U , Edvardsson S., Braathen G., Hagenfeldt L.: 5,10 Methylenetetrahydrofolate reductase deficiency in two patients with different clinical presentations, abstract . J Inherit Metab Dis1996;19(Suppl 1):A42.
13.
Marquet J., Chadefaux B., Bonnefont JP, et al: Methylenetetrahydrofolate reductase deficiency: Prenatal diagnosis and family studies. Prenat Diagn1994;14:29-33.
14.
Ronge E., Kjellman B.: Long term treatment with betaine in methylenetetrahydrofolate reductase deficiency . Arch Dis Child1996;74: 239-241.
15.
Wendel U., Bremer HJ: Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr1984;142:147-150.
16.
Walk D., Kang SS, Horwitz A.: Intermittent encephalopathy, reversible nerve conduction slowing, and MRI evidence of cerebral white matter disease in methylenetetrahydrofolate reductase deficiency. Neurology1994;44:344-347.
17.
Kanwar YS, Manaligod JR, Wong PW: Morphologic studies in a patient with homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Pediatr Res1976;10:598-609.
18.
Haworth JC, Dilling LA, Surtees Rah, et al: Symptomatic and asymptomatic methylenetetrahydrofolate reductase deficiency in two adult brothers. Am J Med Genet1993;45:572-576.
19.
Freeman JM, Finkelstein JD, Mudd SH: Folate-responsive homocystinuria and "schizophrenia". A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity . N Engl JMed1975;292:491-496.
20.
Molloy AM, Daly S., Mills JL, et al: Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations . Lancet1997;349:1591-1593.
21.
Applegarth DA, Vallance HD, Seccombe D.: Are patients with homocystinuria being missed?, letter. EurJPediatr1995;154:589.
22.
Smith KL, Bradley L., Levy HL, Korson MS: Inadequate laboratory technique for amino acid analysis resulting in missed diagnosis of homocystinuria, letter. Clin Chem1998;44:897-898.
23.
Fowler B., Jakobs C.: Post- and prenatal diagnostic methods for the homocystinurias. Eur J Pediatr1998;157(Suppl 2):588-593.
24.
Engelbrecht V., Rassek M., Huisman J., Wendel U.: MR and proton MR spectroscopy of the brain in hyperhomocystinemia caused by methylenetetrahydrofolate reductase deficiency . AJNR Am J Neuroradiol1997;3:536-539.
25.
Clayton PT, Smith I., Harding B., et al: Subacute combined degeneration of the cord, dementia and parkinsonism due to an inborn error of folate metabolism. J Neurol Neurosurg Psychiatry1986; 49:920-927.
Surtees R., Leonard J., Austin S.: Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet1991;338:1550-1554.
28.
Stehouwer CD , Jakobs C.: Abnormalities of vascular function in hyperhomocysteinaemia: Relationship to atherothrombotic disease. Eur J Pediatr1998;157(Suppl 2):S107-S111.
29.
Boers G.: Moderate hyperhomocysteinaemia and vascular disease: Evidence, relevance and the effect of treatment. Eur J Pediatr1998 ;157(Suppl 2):S127-S130.
30.
Goyette P., Christensen B., Rosenblatt DS, Rozen R.: Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Am J Hum Genet1996;59:1268-1275.
31.
Jacques PF, Bostom AG, Williams RR, et al: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation1996; 93:7-9.
32.
van der Put NM, Steegers-Theunissen RP, Frosst P., et al: Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet1995;346:1070-1071.
Bonham JR, Moat SJ, Guthrie Pai, et al: The thermolabile methylenetetrahydrofolate reductase (MTHFR) mutation—a common finding in the UK population, abstract. J Inherit Metab Dis1996; 19(Suppl 1):P46.
35.
de Franchis R., Mandato C., Sebastio G., et al: Moderate hyperhomocysteinemia (HHC) and C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene as a risk factor for atherosclerotic cardiovascular disease (CVD) and neural tube defects (NTD) in Italy, abstract. J Inherit Metab Dis1996;19(Suppl 1):P48.
36.
Harpey JP, Rosenblatt DS, Cooper BA, et al: Homocystinuria caused by 5,10-methylenetetrahydrofolate reductase deficiency: A case in an infant responding to methionine, folinic acid, pyridoxine, and vitamin B12 therapy. J Pediatr1981;98:275-278.
37.
Al-Essa MA, Al Amir A., Rashed M., et al: Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography of the brain, MR spectroscopy, and therapeutic attempts in methylenetetrahydrofolate reductase deficiency. Brain Dev1999;21: 345-349.
38.
Abeling Nggm , van Gennip AH, Blom H., et al: Rapid diagnosis and methionine administration: Basis for a favourable outcome in a patient with methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis1989;22:240-242.
